Prognosis
Monkeypox Vaccine Study Raises Questions About Protection
- Bavarian Nordic’s Jynneos vaccine spurred low antibody levels
- Research suggests using lower dose reduces virus immunity
This article is for subscribers only.
The monkeypox vaccine that’s become the main method doctors use to try to stop the global scourge may be less potent than hoped, new research shows.
The recommended series of shots with Bavarian Nordic A/S’s Jynneos vaccine yielded relatively low levels of monkeypox antibodies with poor capacity to neutralize the virus, researchers at the Erasmus University Medical Center in Rotterdam, Netherlands, said. Those immunized hadn’t been previously infected or vaccinated against smallpox, which is believed to provide some protection against monkeypox. Routine smallpox immunization stopped 50 years ago in the US.